TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6341640

Group type: EXPERIMENTAL
Intervention: Ribavirin aerosol treatment
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 16
Study: 31040088

Group type: EXPERIMENTAL
Intervention: Mannitol, 0.25 g/kg/h
Number of subjects: 52

Group type: COMPARATOR
Intervention: 0.9% saline solution (placebo)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Mannitol
Number of subjects: 52
Study: 28824019

Group type: EXPERIMENTAL
Intervention: Writing training on both Day 1 and Day 2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pinyin typing training on Day 1 and writing training on Day 2
Number of subjects: 0
Study: 25619196

Group type: EXPERIMENTAL
Intervention: Mailed educational materials and follow-up questionnaire
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Physician's recommendation to be screened
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Family history of colon cancer
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Belief that health-care decisions should be mostly left to physicians
Number of subjects: 641
Study: 24999797

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for 8 weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: General information on IBS (Control)
Number of subjects: 90
Study: 22250032

Group type: EXPERIMENTAL
Intervention: IVIG treatment after day 10
Number of subjects: 150

Group type: COMPARATOR
Intervention: IVIG treatment before day 10 (control)
Number of subjects: 150
Study: 20357281

Group type: EXPERIMENTAL
Intervention: Dutasteride (0.5 mg daily)
Number of subjects: 6729

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6729
Study: 17350069

Group type: EXPERIMENTAL
Intervention: Initial training session
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inter-trial interval longer than 3s
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New locations for targets within the texture stimulus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Task-irrelevant targets
Number of subjects: 0
Study: 15709841

Group type: EXPERIMENTAL
Intervention: Behavioral couple therapy for infidelity couples
Number of subjects: 19
Study: 12144005

Group type: EXPERIMENTAL
Intervention: Flow sheet intervention incorporating GINA guidelines
Number of subjects: 122
Study: 9486164

Group type: EXPERIMENTAL
Intervention: Sumatriptan (6 mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 8566638

Group type: EXPERIMENTAL
Intervention: Intravenous atropine 0.02 mg/kg (maximum 0.4 mg)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo (normal saline solution)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Intravenous atropine with meperidine
Number of subjects: 101

Group type: COMPARATOR
Intervention: Meperidine with placebo
Number of subjects: 101
Study: 3123222

Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 24
Study: 29685048

Group type: EXPERIMENTAL
Intervention: EUS-cytology brush (EUS-EB)
Number of subjects: 65

Group type: COMPARATOR
Intervention: EUS-fine needle aspiration (EUS-FNA)
Number of subjects: 65
Study: 27168266

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5mg BID
Number of subjects: 1843

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10mg BID
Number of subjects: 1843

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1843
Study: 24993458

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care from a clinical pharmacist
Number of subjects: 733

Group type: COMPARATOR
Intervention: Routine medical care (control)
Number of subjects: 733
Study: 22683276

Group type: EXPERIMENTAL
Intervention: 0.1% topical clonidine gel applied 3 times a day for 12 weeks
Number of subjects: 179
Study: 20404228

Group type: EXPERIMENTAL
Intervention: Minimally invasive fractional radiofrequency (FRF) treatment
Number of subjects: 15

Group type: COMPARATOR
Intervention: Surgical face-lift
Number of subjects: 15
Study: 19189673

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clerafil Tri-S Bond
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single Bond
Number of subjects: 0

Group type: COMPARATOR
Intervention: Caries-affected dentin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal dentin
Number of subjects: 0
Study: 19164270

Group type: EXPERIMENTAL
Intervention: Physical activity counseling (single session + supportive phone contact every 4 months for 2 years)
Number of subjects: 632

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 632
Study: 15257052

Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Atgam
Number of subjects: 100
Study: 11599643

Group type: EXPERIMENTAL
Intervention: Fluoxetine maintenance treatment during a 62-week study
Number of subjects: 55
Study: 9480606

Group type: EXPERIMENTAL
Intervention: Primary endoprosthetic replacement
Number of subjects: 30

Group type: COMPARATOR
Intervention: Minimal osteosynthesis
Number of subjects: 30
Study: 8281707

Group type: EXPERIMENTAL
Intervention: Pure FSH (225 IU/day)
Number of subjects: 34

Group type: COMPARATOR
Intervention: hMG (225 IU/day)
Number of subjects: 34
Study: 3321539

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 11740220

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Number of subjects: 18

Group type: COMPARATOR
Intervention: Unoprostone 0.12%
Number of subjects: 18
Study: 30325696

Group type: EXPERIMENTAL
Intervention: Acute Physical Effort (APE) - 30-min walk at 65%-75% of age-predicted maximal HR
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Activity Orthostatic Position (AS) - changing from supine to standing position
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control Group (CG) - healthy volunteers
Number of subjects: 14
Study: 28860019

Group type: EXPERIMENTAL
Intervention: empagliflozin
Number of subjects: 2286

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2286
Study: 27067479

Group type: EXPERIMENTAL
Intervention: Riociguat
Number of subjects: 396
Study: 24473534

Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Health and wellness education (HW)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Wait list (WL)
Number of subjects: 54
Study: 22695403

Group type: EXPERIMENTAL
Intervention: Soap-and-water body wipes
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: 70% isopropyl alcohol (IPA) body wipes
Number of subjects: 151

Group type: COMPARATOR
Intervention: No treatment (CONTROL)
Number of subjects: 151
Study: 20360542

Group type: EXPERIMENTAL
Intervention: Hyperthyroidism patients
Number of subjects: 3176

Group type: COMPARATOR
Intervention: Comparison cohort (without hyperthyroidism)
Number of subjects: 3176
Study: 17409767

Group type: EXPERIMENTAL
Intervention: High dialysate calcium (HdCa) concentration of 1.75 mmol/l
Number of subjects: 14

Group type: COMPARATOR
Intervention: Low dialysate calcium (LdCa) concentration of 1.25 mmol/l
Number of subjects: 14
Study: 14670399

Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 106

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 106
Study: 11779668

Group type: EXPERIMENTAL
Intervention: 4 mg or 2 mg of oral naloxone, three times daily
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 9690726

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate 3 mg/60 mL enema (BDP)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Prednisolone sodium phosphate 30 mg/60 mL enema (PP)
Number of subjects: 157
Study: 7916398

Group type: EXPERIMENTAL
Intervention: Enteral feeding
Number of subjects: 24

Group type: COMPARATOR
Intervention: Total parenteral nutrition
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups (Enteral feeding and Total parenteral nutrition)
Number of subjects: 24
Study: 2627930

Group type: EXPERIMENTAL
Intervention: Water and sanitation intervention (provision of handpumps, construction of latrines, hygiene education)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 200
Study: 29938557

Group type: EXPERIMENTAL
Intervention: Schema-focused cognitive group therapy (11 sessions)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Waiting list control group (no immediate treatment)
Number of subjects: 42
Study: 25157500

Group type: EXPERIMENTAL
Intervention: Collaborative depression care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 23257208

Group type: EXPERIMENTAL
Intervention: NT‐proBNP‐guided, intensive patient management (BMC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multidisciplinary care (MC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 0
Study: 21502567

Group type: EXPERIMENTAL
Intervention: Ghrelin (5 pmol/kg per minute for 1 hour)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 26
Study: 18931204

Group type: EXPERIMENTAL
Intervention: 5% Human Albumin (HA), n = 25
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hydroxyethyl starch (6% HES 130/0.4), n = 25
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups (HA and HES)
Number of subjects: 50
Study: 16595219

Group type: EXPERIMENTAL
Intervention: hMG and intrauterine insemination (IUI)
Number of subjects: 135

Group type: COMPARATOR
Intervention: luteal phase down‐regulation with LA, hMG, and IUI
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: hMG and IUI
Number of subjects: 135
Study: 12826159

Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy
Number of subjects: 86

Group type: COMPARATOR
Intervention: No anticoagulant therapy
Number of subjects: 86
Study: 10702883

Group type: EXPERIMENTAL
Intervention: 100 mg cilostazol suspension
Number of subjects: 0

Group type: COMPARATOR
Intervention: 100 mg cilostazol tablet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 50 mg cilostazol ethanolic solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High fat meal with 100 mg cilostazol
Number of subjects: 0
Study: 8726790

Group type: EXPERIMENTAL
Intervention: Paroxetine (20 to 40 mg daily)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Maprotiline (50 to 150 mg daily)
Number of subjects: 71
Study: 1945512

Group type: EXPERIMENTAL
Intervention: Preoperative venogram
Number of subjects: 0

Group type: COMPARATOR
Intervention: No preoperative venogram
Number of subjects: 0
Study: 7067470

Group type: EXPERIMENTAL
Intervention: Stepped Care (SC) treatment with extensive efforts to reduce barriers to care
Number of subjects: 10940

Group type: COMPARATOR
Intervention: Referral to community sources for care (RC)
Number of subjects: 10940

Group type: EXPERIMENTAL
Intervention: Educational level as a predictor of drug adherence
Number of subjects: 10940

Group type: EXPERIMENTAL
Intervention: Pill counts
Number of subjects: 10940
Study: 29212345

Group type: EXPERIMENTAL
Intervention: iOS-based app with transmitter/disposable sensor and manualized intervention
Number of subjects: 33

Group type: COMPARATOR
Intervention: Standard behavioral treatment
Number of subjects: 33
Study: 29322810

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 23
Study: 26544859

Group type: EXPERIMENTAL
Intervention: Virtual walking treatment
Number of subjects: 44
Study: 24569459

Group type: EXPERIMENTAL
Intervention: KRN23 (0.003-0.3 mg/kg i.v. or 0.1-1 mg/kg s.c.)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 25780646

Group type: EXPERIMENTAL
Intervention: Chukyu (spine-healing) pharmacopuncture
Number of subjects: 45

Group type: COMPARATOR
Intervention: Normal saline pharmacopuncture
Number of subjects: 45
Study: 19046855

Group type: EXPERIMENTAL
Intervention: Intranasal midazolam 2.5 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Intranasal midazolam 5.0 mg
Number of subjects: 17

Group type: COMPARATOR
Intervention: Intravenous midazolam 2.5 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Intranasal midazolam (both doses)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Nasal endoscopy
Number of subjects: 17
Study: 18086982

Group type: EXPERIMENTAL
Intervention: Individualized attention from a massage therapist (20 minutes)
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Back massage by a massage therapist each evening for up to 5 postoperative days
Number of subjects: 605

Group type: COMPARATOR
Intervention: Control (routine care)
Number of subjects: 605
Study: 14720531

Group type: EXPERIMENTAL
Intervention: Amiodarone 400mg BD for 2 weeks prior to DCCV and 200mg daily for 8 weeks followed by placebo for 44 weeks
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Amiodarone 400mg BD for 2 weeks then 200mg daily for 52 weeks
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study: 11153968

Group type: EXPERIMENTAL
Intervention: Actor version of the Symptom Interpretation Scale (SIS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observer version of the Symptom Interpretation Scale (SIS)
Number of subjects: 0
Study: 9227184

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 8190556

Group type: EXPERIMENTAL
Intervention: Lorabid
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Keflex
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Suprax
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ceclor
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cefzil
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Augmentin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Vantin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: V-Cillin-K
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Veetids
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sulfatrim
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pediazole
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dynapen
Number of subjects: 12
Study: 3069476

Group type: EXPERIMENTAL
Intervention: Felodipine (n = 11)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (n = 12)
Number of subjects: 23
Study: 26588940

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Waiting list (WL)
Number of subjects: 103
Study: 28242632

Group type: EXPERIMENTAL
Intervention: Eribulin 1.4 mg/m2 intravenously on days 1 and 8
Number of subjects: 452

Group type: COMPARATOR
Intervention: Dacarbazine 850, 1,000, or 1,200 mg/m2 intravenously on day 1 of a 21-day cycle
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Eribulin (in liposarcoma subgroup)
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 452
Study: 25831464

Group type: EXPERIMENTAL
Intervention: Efavirenz
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Atazanavir
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Lopinavir
Number of subjects: 89

Group type: COMPARATOR
Intervention: All treatment arms
Number of subjects: 89
Study: 23255536

Group type: EXPERIMENTAL
Intervention: Immediate reporting arm
Number of subjects: 1502

Group type: COMPARATOR
Intervention: Delayed reporting arm
Number of subjects: 1502

Group type: COMPARATOR
Intervention: Both arms
Number of subjects: 1502
Study: 21094951

Group type: EXPERIMENTAL
Intervention: Oral ibuprofen
Number of subjects: 102

Group type: COMPARATOR
Intervention: Intravenous ibuprofen
Number of subjects: 102
Study: 19186315

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg (adjustable to 25 mg or 100 mg based on patient response)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study: 16760504

Group type: EXPERIMENTAL
Intervention: Folic acid (500-1,500 microg/day) plus oral iron
Number of subjects: 1035

Group type: COMPARATOR
Intervention: Oral iron alone
Number of subjects: 1035
Study: 14985229

Group type: EXPERIMENTAL
Intervention: Fat (50 g/m² body surface)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Glucose (37.5 g/m²)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Fat and glucose (mixed test)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Water (control test)
Number of subjects: 6
Study: 11301639

Group type: EXPERIMENTAL
Intervention: Sea water
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 500 mM NaCl
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 mM KCl
Number of subjects: 0

Group type: COMPARATOR
Intervention: Deionized water
Number of subjects: 0
Study: 9266794

Group type: EXPERIMENTAL
Intervention: 6F guiding catheter
Number of subjects: 460

Group type: COMPARATOR
Intervention: 7F or 8F guiding catheter
Number of subjects: 460
Study: 8499958

Group type: EXPERIMENTAL
Intervention: Systen (3.2 mg micronized 17 beta-estradiol transdermal patch)
Number of subjects: 745

Group type: COMPARATOR
Intervention: Estraderm (older transdermal therapeutic system)
Number of subjects: 745
Study: 3544753

Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase (group B)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase (group D)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional treatment (group A)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional treatment (group C)
Number of subjects: 54
Study: 2600130

Group type: EXPERIMENTAL
Intervention: St Jude Medical (SJM) prosthesis
Number of subjects: 357

Group type: COMPARATOR
Intervention: Björk-Shiley valve (BSM) and Starr-Edwards 6120 valve prosthesis
Number of subjects: 357
Study: 31409691

Group type: EXPERIMENTAL
Intervention: Maternal voice exposure during the first or second 6 hours of polysomnography
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Maternal voice exposure
Number of subjects: 47
Study: 27810126

Group type: EXPERIMENTAL
Intervention: Juzen-taiho-to (JTT) 0.10-0.25g/kg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment alone (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Juzen-taiho-to (JTT)
Number of subjects: 0
Study: 25248648

Group type: EXPERIMENTAL
Intervention: 0.1% ropivacaine (8 ml h(‐1))
Number of subjects: 24

Group type: COMPARATOR
Intervention: 0.4% ropivacaine (2 ml h(‐1))
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both concentrations (0.1% and 0.4%)
Number of subjects: 24
Study: 23895863

Group type: EXPERIMENTAL
Intervention: Three-port transumbilical endoscopic cholecystectomy (group A)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional 4-port routine endoscopic cholecystectomy (group B)
Number of subjects: 32
Study: 21490141

Group type: EXPERIMENTAL
Intervention: Video game play
Number of subjects: 22

Group type: COMPARATOR
Intervention: Rest in a sitting position
Number of subjects: 22
Study: 19398603

Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Pitavastatin 2 mg
Number of subjects: 11
Study: 16621438

Group type: EXPERIMENTAL
Intervention: 20% CO2 challenge
Number of subjects: 473

Group type: COMPARATOR
Intervention: Room air control
Number of subjects: 473
Study: 15342297

Group type: EXPERIMENTAL
Intervention: Patients presenting during peak hours (Monday to Friday 8a.m. to 8 p.m., n = 1,047)
Number of subjects: 2082

Group type: COMPARATOR
Intervention: Patients presenting during off-peak hours (weeknights from 8 p.m. to 8 a.m. and weekends, n = 989)
Number of subjects: 2082
Study: 11331717

Group type: EXPERIMENTAL
Intervention: Intervention group (home visitation every other week for 1 year)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 181

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 181
Study: 9232342

Group type: EXPERIMENTAL
Intervention: 1 g of ascorbic acid
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: 2 g of ascorbic acid
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: 4 g of ascorbic acid
Number of subjects: 228

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 228
Study: 8489978

Group type: EXPERIMENTAL
Intervention: Intravenous droperidol (2.5 mg)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control (no droperidol)
Number of subjects: 107
Study: 3501274

Group type: EXPERIMENTAL
Intervention: rIFN-alpha (5.5 megaunits/m2 body surface daily for 21 days, then twice a week for six months)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 20
Study: 30698538

Group type: EXPERIMENTAL
Intervention: Early seizures (occurred from 1 to 7 days after TBI)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Late seizures (occurred later than 7 days after TBI)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Severe TBI in patients with early seizures
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Predictors of early and late PTS
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Risk of posttraumatic epilepsy (PTE)
Number of subjects: 237
Study: 27036113

Group type: EXPERIMENTAL
Intervention: Diet intervention (specific macronutrient content not detailed)
Number of subjects: 111
Study: 23131287

Group type: EXPERIMENTAL
Intervention: Chenxia Sijunzi decoction
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Western medicine (multienzyme tablets and mosapride dispersible tablets)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (routine symptomatic treatment)
Number of subjects: 80
Study: 21157174

Group type: EXPERIMENTAL
Intervention: Cognitive enhancement group training program (10 sessions, once a week for 10 weeks)
Number of subjects: 87
Study: 17993948

Group type: EXPERIMENTAL
Intervention: Patients with severe head trauma who became brain dead
Number of subjects: 388

Group type: COMPARATOR
Intervention: Various therapies to maintain hemodynamic stability for organ donation
Number of subjects: 388
Study: 15884097

Group type: EXPERIMENTAL
Intervention: Health education intervention designed to improve mammography screening
Number of subjects: 897
Study: 12206622

Group type: EXPERIMENTAL
Intervention: 24 units/kg body weight
Number of subjects: 48

Group type: COMPARATOR
Intervention: 8 units/kg body weight
Number of subjects: 48
Study: 9927272

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 350